{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:18:07Z","timestamp":1787062687698,"version":"build-2736575974"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1704,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1177\/0091270010362906","type":"journal-article","created":{"date-parts":[[2010,3,29]],"date-time":"2010-03-29T23:33:56Z","timestamp":1269905636000},"page":"53-59","source":"Crossref","is-referenced-by-count":14,"title":["Effect of CYP2B6 Genotype on the Pharmacokinetics of Sibutramine and Active Metabolites in Healthy Subjects"],"prefix":"10.1002","volume":"51","author":[{"given":"Jae Yong","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Bok","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungsoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"issue":"suppl 1","key":"10.1177\/0091270010362906-BIB1|cit1","first-page":"S18","article-title":"Sibutramine: a novel anti-obesity drug: a review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine","volume":"22","author":"Heal","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1177\/0091270010362906-BIB2|cit2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00008571-200308000-00003","article-title":"Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism","volume":"13","author":"Hauner","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1177\/0091270010362906-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1053\/j.gastro.2008.07.009","article-title":"A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults","volume":"135","author":"Grudell","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1177\/0091270010362906-BIB4|cit4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s002280050565","article-title":"Sibutramine pharmacokinetics in young and elderly healthy subjects","volume":"54","author":"Hind","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1177\/0091270010362906-BIB5|cit5","first-page":"345","article-title":"A pilot study to evaluate the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions","volume":"7","author":"Abolfathi","year":"2004","journal-title":"J Pharm Pharm Sci"},{"issue":"suppl 1","key":"10.1177\/0091270010362906-BIB6|cit6","first-page":"S25","article-title":"Sibutramine: a review of the pharmacology of a novel anti-obesity agent","volume":"21","author":"Stock","year":"1997","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1177\/0091270010362906-BIB7|cit7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0028-3908(89)90048-8","article-title":"The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride","volume":"28","author":"Luscombe","year":"1989","journal-title":"Neuropharmacology"},{"key":"10.1177\/0091270010362906-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/dmd.108.020727","article-title":"Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes","volume":"36","author":"Bae","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1177\/0091270010362906-BIB9|cit9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00008571-200310000-00005","article-title":"Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6","volume":"13","author":"Kirchheiner","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1177\/0091270010362906-BIB10|cit10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/FPC.0b013e328045c4fb","article-title":"Genetic polymorphisms of CYP2B6 affect the pharmacokinetics\/pharmacodynamics of cyclophosphamide in Japanese cancer patients","volume":"17","author":"Nakajima","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1177\/0091270010362906-BIB11|cit11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2125.2008.03321.x","article-title":"Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa","volume":"67","author":"Ekhart","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1177\/0091270010362906-BIB12|cit12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00008571-199906000-00004","article-title":"Human CYP2B6: expression, inducibility and catalytic activities","volume":"9","author":"Gervot","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1177\/0091270010362906-BIB13|cit13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2217\/14622416.8.7.743","article-title":"Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance","volume":"8","author":"Zanger","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1177\/0091270010362906-BIB14|cit14","unstructured":"Mo SL Liu YH Duan W Wei MQ Kanwar JR Zhou SF Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6 [published online ahead of print September 1, 2009] Curr Drug Metab"},{"key":"10.1177\/0091270010362906-BIB15|cit15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/14622416.8.6.547","article-title":"Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro","volume":"8","author":"Desta","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1177\/0091270010362906-BIB16|cit16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1124\/jpet.107.133306","article-title":"Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver","volume":"325","author":"Hofmann","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1177\/0091270010362906-BIB17|cit17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1124\/dmd.31.4.398","article-title":"Functional characterization of cytochrome P450 2B6 allelic variants","volume":"31","author":"Jinno","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1177\/0091270010362906-BIB18|cit18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":"Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals","volume":"81","author":"Rotger","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1177\/0091270010362906-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1124\/dmd.104.001107","article-title":"Haplotype structure and allele frequencies of CYP2B6 in a Korean population","volume":"32","author":"Cho","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1177\/0091270010362906-BIB20|cit20","unstructured":"Arenaz I Vicente J Fanlo A et al Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans [published online ahead of print August 14, 2009] Fundam Clin Pharmacol"},{"key":"10.1177\/0091270010362906-BIB21|cit21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00008571-200404000-00002","article-title":"Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes","volume":"14","author":"Hesse","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1177\/0091270010362906-BIB22|cit22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clpt.2006.03.010","article-title":"Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity","volume":"80","author":"Loboz","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1177\/0091270010362906-BIB23|cit23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss","volume":"7","author":"Bray","year":"1999","journal-title":"Obes Res"},{"key":"10.1177\/0091270010362906-BIB24|cit24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects","volume":"116","author":"Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1177\/0091270010362906-BIB25|cit25","volume-title":"Meridia (sibutramine) [package insert]","year":"2000"},{"key":"10.1177\/0091270010362906-BIB26|cit26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0028-3908(03)00136-9","article-title":"Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain","volume":"45","author":"Miksys","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1177\/0091270010362906-BIB27|cit27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/clpt.2009.145","article-title":"Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects","volume":"86","author":"Kim","year":"2009","journal-title":"Clin Pharmacol Ther"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270010362906","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1177\/0091270010362906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T08:57:46Z","timestamp":1657789066000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1177\/0091270010362906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"URL":"https:\/\/doi.org\/10.1177\/0091270010362906","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}